Introduction Asthma is an important healthcare problem affecting millions in the United States. Additionally, a large proportion of patients with asthma suffer from obesity. These patients exhibit poor asthma control and reduced therapy response, increasing utilization of healthcare resources. Pulmonary symptoms improve after bariatric surgery (BS), and we hypothesized that asthma medication usage would decrease following BS. Methods A retrospective data analysis was performed in adult patients from a single institution's database. Patients with obesity using at least one asthma medication pre-operatively who underwent BS were studied for up to 3-years post-operation. Poisson generalized linear mixed models for repeated measures were used to evaluate the effects of time and procedure type on the number of asthma medication. Results Bariatric patients with at least one prescribed asthma medication (mean 1.4 ± 0.6) were included (n = 751). The mean age at time of operation was 46.8 ± 11.6 years, mean weight was 295.9 ± 57 lbs, and mean body mass index (BMI) was 49 ± 8.2 kg/m 2 ; 87.7% were female, 33.4% had diabetes, 44.2% used gastroesophageal reflux disease (GERD) medication, and 64.4% used hypertension medication. The most common procedure was Roux-en-Y gastric bypass (79%), followed by sleeve gastrectomy (10.7%), adjustable gastric banding (8.1%), and duodenal switch (2.3%). The mean number of prescribed asthma medications among all procedures decreased by 27% at 30 days post-operation (p < 0.0001), 37% at 6 months (p < 0.0001), 44% at 1 year (p < 0.0001), and 46% at 3 years (p < 0.0001) after adjusting for risk factors. No significant differences in medication use over time between procedure types were observed. In the adjusted analysis, the mean number of asthma medications was 12% higher in patients using at least one GERD medication (p = 0.015) and 8% higher with 10-unit increase in pre-operative BMI (p = 0.006). Conclusion BS significantly decreases asthma medication use starting 30 days post-operation with a sustained reduction for up to 3 years.
3
amounts of healthcare resources [7, 8, 12, 13] . Several studies have proposed a potential causal association between both conditions [2, 12, 14, 15] therefore targeting weight loss in individuals with both obesity and asthma is likely to improve asthma control.
Currently, bariatric surgery is the most effective treatment for morbid obesity, resulting in sustained weight loss and improvement of co-morbidities [16] with maximal weight loss typically occurring 1-2 years after surgery [7, 17] . Additionally, studies have demonstrated that bariatric surgery is capable of producing significant improvements in pulmonary symptoms such as those caused by obstructive sleep apnea [7, [18] [19] [20] . In particular, patients with asthma exhibited improved small airway function and decreased numbers of mast cells in the airway following bariatric surgery [21] . The present study evaluated the hypothesis that the need for asthma medications would decrease over time after bariatric surgery.
Materials and methods
After Institutional Review Board approval, a retrospective analysis of a prospectively maintained single institution database was performed. Patients aged 18 or above, with at least one asthma medication prescribed pre-operatively who underwent bariatric surgery in Duke University Medical Center between January, 2000 and October, 2015 were identified. A list of the asthma, gastroesophogeal reflux disease (GERD), and hypertension medications used in our analysis is shown in Table 1 . Patient reported medications count was gathered from our institution medical records. These asthma medications were included after pulmonologist review and based on recommended medications in the National guidelines for asthma management [22] . Baseline and post-operative data including demographics, weight and BMI, co-morbidities, number of prescribed asthma, GERD and hypertension medications, type of procedure, and complications were reviewed. Patients were followed up at 30 days, 90 days, 6 months, 1 year, years, and 3 years post-operation. Continuous variables were summarized using appropriate measures of location and variability and compared using Kruskal-Wallis test, whereas categorical variables were presented as frequencies and percentages and compared using Fisher's exact test. Over 85% of the patients had missing weight/asthma medication information after 4 years post-operation, therefore we only included records up to 3 years post-operation for the analysis. Approximately 69% of patients had complete data up to 1 year post-operation. Since missing data were present in the dataset, we investigated the missing data pattern before we determined the model of longitudinal data analysis. We found that younger patients were more likely to become loss to follow-up regardless of their weights or severity of asthma, and thus we assumed a Missing At Random (MAR) mechanism and a Generalized Linear Mixed Model (GLMM) was considered. Our primary outcome was the longitudinal number of prescribed asthma medications assessed pre-operatively and post-operatively. A Poisson GLMM with a log link for repeated measures was fit to evaluate the effect of time and procedure type, on number of asthma medications, while adjusting for risk factors including age, gender, race, pre-operative diabetes, pre-operative BMI, pre-operative use of hypertension medications (at least one medication vs. none), and preoperative use of GERD medications (at least one medication vs. none). The GERD and hypertension medications used in our analyses (Table 1) were chosen based on national guidelines for management [23, 24] . Additionally, we performed a separate analysis to evaluate the trend of number of prescribed asthma medications for each procedure type by including interaction terms of procedure types and time. BMI was also assessed longitudinally as a secondary outcome using linear mixed effect model. All analyses were performed using R 3.3.1 (R Core Team, Vienna, Austria) and SAS 9.4 (SAS Institute Inc., Cary, NC).
Results
The study population consisted of 751 bariatric patients with at least one asthma medication prescribed preoperatively (mean 1.4 ± 0.6). Mean age at operation was 46.8 ± 11.6 years, mean weight was 295.9 ± lbs, BMI was 49 ± 8.2 kg/m 2 ; 87.7% were females, 33.4% had diabetes, 44.2% used GERD medication, and 64.4% used hypertension medication. The most common type of procedure performed was Roux-en-Y Gastric Bypass (79%), followed by Sleeve Gastrectomy (10.7%), Adjustable Gastric Band (8.1%), and Duodenal Switch (2.3%). Demographic data are summarized in Table 2 .
The unadjusted number of prescribed asthma medications were assessed pre-operatively and post-operatively and summarized in Table 3 . The pre-operative average count of asthma medications was 1.4 ± 0.6, and it became 1 ± 0.8 at 30-day post-operation and 0.8 ± 0.8 at 1-year post-operation. Table 4 displays the results of Poisson GLMM of the mean counts of prescribed asthma medications over time. Overall, there was a significant time effect on the number of asthma medications used (p < 0.0001) while adjusting for all other risk factors. In particular, we saw a significant decrease in the number of asthma medications used after bariatric surgery in our cohort. The subject-specific rate ratios (RRs) at 30 days post-operation compared to pre-operation was 0.73 (95% confidence interval (CI) 0.66-0.80). Similarly, the average number of asthma medications used among all procedures was 31% lower at 90 days (RR 0.69, 95% CI 0.63-0.77), 37% lower at 6 months (RR 0.63, 95% CI 0.56-0.70), 44% lower at 1 year (RR 0.56, 95% CI 0.50-0.63), 48% lower at 2 years (RR 0.52, 95% CI 0.44-0.60), and 46% lower at 3 years (RR 0.54, 95% CI 0.45-0.65). We did not find a significant effect of procedure (Type III F tests of procedure effect p = 0.687). However, we detected significant effects of pre-operative GERD medication use (p = 0.0145) and pre-operative BMI (p = 0.0055) on the number of asthma medication. Specifically, patients reporting use of at least one pre-operative GERD medication were associated with 12% higher asthma medication use compared to those not reporting use of pre-operative GERD medications (RR 1.12, 95% CI 1.02-1.23, p = 0.015). With a 10-unit increase in pre-operative BMI, the average number of prescribed asthma medications was 8% higher (RR 1.08, 95% CI 1.02-1.14, p = 0.0065). All other risk factors (age, race, gender, pre-operative diabetes, and pre-operative hypertension medication) were not significant in explaining the variation in the number of asthma medication. The effect of time on number of prescribed asthma medications within each procedure was significant for all procedures except for DS (p = 0.1153). The subject-specific RRs at 1-year postoperation compared to pre-operation for each procedure type can be found in Table 5 .
Pre-operative and post-operative BMIs by procedure types are summarized in Table 6 . Mean BMI was decreased from pre-operative 49 ± 8.2 kg/m 2 to 45.2 ± 8 kg/ m 2 at 30-day post-operation, and it was further reduced to 34.6 ± 7.7 kg/m 2 at 1-year post-operation. Using a linear mixed effect model that adjusted for confounders, we detected significant interaction between procedure types and time (p < 0.0001), and the results are shown in Table 7 . DS patients had the largest post-operative BMI loss (mean change at 1-year: − 19.87 kg/m 2 , 95% CI − 21.93 to − 17.81) whereas AGB patients had the smallest post-operative BMI 
Discussion
During the last decades the prevalence of asthma has increased steadily along with the prevalence of obesity, suggesting a potential relationship between these conditions [25] . Many studies [26] [27] [28] and the American Thoracic Society have concluded that obesity is a risk factor for: (1) development of de novo asthma, and (2) for complicating management in previously-diagnosed asthmatic patients [29] . The physio-pathological mechanism of this relationship is not entirely understood [30, 31] and may differ by asthma phenotypes. Nevertheless, proinflammatory effects of leptin and other obesity-related hormones may contribute to airway hyperreactivity, and, along with the restricted lung mechanics observed in obesity, these combined effects play an important role supporting the association between obesity and asthma [25] . Camargo et al. [10] studied the incidence of asthma in a large prospective cohort of adult subjects and found that increased BMI is an independent factor, significantly associated with the risk of developing adult-onset asthma requiring treatment with at least 1 medication (p < 0.001). Likewise, Gibeon et al. [32] studied 600 patients with asthma and classified them into three groups according to their BMI: normal-weight, overweight, and obese. They found that increased BMI was significantly associated with increased use of asthma maintenance and rescue medication, concluding that asthma symptoms may be difficult to control in overweight and obese populations. Similarly, we found that pre-operative BMI has a significant effect on number of asthma medication after adjusting for other risk factors (p = 0.006). Specifically, we found that patients with lower BMI utilize less asthma medications compared to patients with higher BMI.
Additionally, we found a strong relationship between the pre-operative numbers of asthma medications and the presence of GERD (p = 0.0145), as the use of asthma medication was 12% higher in this population after adjusting for other risk factors. This finding is comparable with other studies that classify GERD as part of the inflammatory conditions contributing to the intensification of respiratory symptoms among patients with obesity [10, 33] .
Bariatric surgery improves obesity-related co-morbidities as well as respiratory conditions such as obstructive sleep apnea [34, 35] . Furthermore, evidence suggests that bariatric surgery results in reduced medication requirements to control pulmonary symptoms [36] . In our cohort, we observed that patients significantly reduced asthma medication use over time after bariatric surgery (p < 0.001). As early as 30 days post-operation, the number of prescribed asthma medications was 27% lower than the pre-operative average number. This reduction was found to be progressive, as at 90 days, 6 months, 1 year, and 2 years after surgery the use of asthma medications was 31%, 37%, 44%, and 48% lower than the pre-operative average, respectively. These results are consistent with other studies where a significant reduction in the use of asthma medication was also reported. Reddy et al. [36] studied over thirteen thousand patients who underwent bariatric surgery and found that 18.6% of the population was diagnosed with asthma and used medication before surgery. One year after bariatric surgery, 40% of the patients significantly reduced the number of asthma medications required for asthma control. Similarly, Sikka et al. [15] studied 320 patients with at least one respiratory medication used before bariatric surgery and found a significant reduction of medication usage 1 year post-bariatric surgery. Our study extends these findings in that we report that patients with asthma and obesity who undergo bariatric surgery experience asthma symptom control benefits immediately after surgery, and this effect is sustained up to 3 years following their surgery.
The technique and practice patterns for all procedures have remained fairly constant in our department over the extended study timeframe. We did not find a significant Table 4 Poisson generalized linear mixed effect model adjusted subject-specific rate ratios (RRs) of count of asthma medications Model excludes follow-ups without asthma medication information. There were 3608 observations RR rate ratio, CI confidence interval 1.08 (1.02, 1.14) 0.0055 Table 5 Procedure type specific adjusted subject-specific rate ratios (RRs) at 1-year post-operation compared to pre-operation for count of asthma medications
Poisson generalized linear mixed effect model was fit and adjusted for time, procedure types, time × procedure types interaction, age, gender, race, pre-operative BMI, pre-operative diabetes types, pre-operative hypertension medication, and pre-operative GERD medication difference in the reduction of asthma medication use between bariatric procedures, suggesting that patients of all procedure types changed the number of asthma medications used over time in the same pattern. In addition, we found that among those patients taking at least one asthma medication, significant reduction in BMI was achieved at 30 days and 1 year post-operatively, and this reduction in BMI was sustained for 3 years, regardless of the procedure type. Therefore, pre-operative asthma medication use does not inhibit weight loss following bariatric surgery in all procedures. These findings can be related to the fact that most patients in our cohort underwent RYGB, making the sample size of other procedures too small to detect a difference, which represents the greater limitation of this study. Furthermore, our study cannot show a causal relationship between post-operative asthma medication use reduction and BMI reduction using our data set. Although we demonstrate a significant association of bariatric surgery with (1) a decrease in asthma medication use and (2) reduced BMI over three years, we cannot yet disentangle whether it is a reduction in BMI that causes the observed surgery-associated reduction in asthma medication use over time, or if the post-operative reduction in asthma medication use occurs independently of weight loss. Further analyses of data in ongoing studies in both human asthma patients and animal models of allergic and non-allergic airways disease that isolate the effects of weight loss and bariatric surgery will establish the individual impact of each of these interventions. By including time and procedure type interaction, we also tested the effect of time on number of prescribed asthma medications within each procedure. We found that the effect of time was significant for all procedures except for DS. However, as noted previously, DS group is comprised of a relatively low number of patients which makes it difficult to reach statistical significance in this analysis. In summary, our results showed that the pre-operative number of medications required for the treatment of asthma is strongly influenced by BMI and GERD. Additionally, our results indicate that bariatric surgery reduces the usage of asthma medications starting 30 days post-operation and that this reduction is sustained up to 3 years after surgery. Therefore, bariatric surgery, regardless of procedure type, is a beneficial intervention specifically for patients with asthma and obesity to improve asthma symptoms and control. Our ongoing investigations of the physiological and metabolic changes that occur with bariatric surgery will evaluate specific cellular and molecular mechanisms of improved airway inflammation, resistance and remodeling that impact asthma control and medication use. Further studies with larger cohorts would be necessary to establish the impact of each type of bariatric procedure on the required number of asthma medications over time, in order to better address the management of obesity in asthmatic patients. 
